Last reviewed · How we verify

Imatinib mesylate (STI571) — Competitive Intelligence Brief

Imatinib mesylate (STI571) (Imatinib mesylate (STI571)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor BCR-ABL, PDGF receptor, c-KIT Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Imatinib mesylate (STI571) (Imatinib mesylate (STI571)) — M.D. Anderson Cancer Center. Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and other cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Imatinib mesylate (STI571) TARGET Imatinib mesylate (STI571) M.D. Anderson Cancer Center phase 3 Tyrosine kinase inhibitor BCR-ABL, PDGF receptor, c-KIT
Inlyta Axitinib Pfizer marketed Receptor tyrosine kinase inhibitor Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3 2012-01-01
Vizimpro Dacomitinib Pfizer Inc. marketed Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Sunitinib Malate (SU011248) Sunitinib Malate (SU011248) H. Lee Moffitt Cancer Center and Research Institute marketed Multi-targeted tyrosine kinase inhibitor VEGFR, PDGFR, KIT, FLT3
Osimertinib (Osi) Osimertinib (Osi) AbbVie marketed EGFR tyrosine kinase inhibitor (third-generation) EGFR (Epidermal Growth Factor Receptor)
imatinib (IM) imatinib (IM) First Affiliated Hospital, Sun Yat-Sen University marketed Tyrosine kinase inhibitor BCR-ABL, KIT, PDGFRA
DW6012(Dasidiem tab. 10/100mg) DW6012(Dasidiem tab. 10/100mg) Dong Wha Pharmaceutical Co. Ltd. marketed Tyrosine kinase inhibitor combination BCR-ABL, SRC family kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

  1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
  2. Centre Leon Berard · 2 drugs in this class
  3. AB Science · 2 drugs in this class
  4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
  6. Angion Biomedica Corp · 1 drug in this class
  7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
  8. Chang-Ming Huang, Prof. · 1 drug in this class
  9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
  10. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imatinib mesylate (STI571) — Competitive Intelligence Brief. https://druglandscape.com/ci/imatinib-mesylate-sti571. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: